Nanovi of Copenhagen, Denmark, has secured funding for its first product: an injectable tissue liquid marker used to improve accuracy in radiation treatment of patients with cancer.
SEED Capital of Kongens Lyngby invested in Nanovi earlier this year, and now Vækstfonden of Hellerup has joined in a second closing. These first investments of 600,000 euros ($807,000 U.S.) will allow Nanovi to develop a proof-of-concept trial for BioXmark, the company said.
BioXmark will be available for commercial use in Europe in 2015, according to Nanovi.
